Cargando…
A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease
Characterisation and diagnosis of idiopathic Parkinson’s disease (iPD) is a current challenge that hampers both clinical assessment and clinical trial development with the potential inclusion of non-PD cases. Here, we used a targeted mass spectrometry approach to quantify 38 metabolites extracted fr...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516864/ https://www.ncbi.nlm.nih.gov/pubmed/34650080 http://dx.doi.org/10.1038/s41531-021-00239-x |
_version_ | 1784583886220558336 |
---|---|
author | Klatt, Stephan Doecke, James D. Roberts, Anne Boughton, Berin A. Masters, Colin L. Horne, Malcolm Roberts, Blaine R. |
author_facet | Klatt, Stephan Doecke, James D. Roberts, Anne Boughton, Berin A. Masters, Colin L. Horne, Malcolm Roberts, Blaine R. |
author_sort | Klatt, Stephan |
collection | PubMed |
description | Characterisation and diagnosis of idiopathic Parkinson’s disease (iPD) is a current challenge that hampers both clinical assessment and clinical trial development with the potential inclusion of non-PD cases. Here, we used a targeted mass spectrometry approach to quantify 38 metabolites extracted from the serum of 231 individuals. This cohort is currently one of the largest metabolomic studies including iPD patients, drug-naïve iPD, healthy controls and patients with Alzheimer’s disease as a disease-specific control group. We identified six metabolites (3-hydroxykynurenine, aspartate, beta-alanine, homoserine, ornithine (Orn) and tyrosine) that are significantly altered between iPD patients and control participants. A multivariate model to predict iPD from controls had an area under the curve (AUC) of 0.905, with an accuracy of 86.2%. This panel of metabolites may serve as a potential prognostic or diagnostic assay for clinical trial prescreening, or for aiding in diagnosing pathological disease in the clinic. |
format | Online Article Text |
id | pubmed-8516864 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-85168642021-10-29 A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease Klatt, Stephan Doecke, James D. Roberts, Anne Boughton, Berin A. Masters, Colin L. Horne, Malcolm Roberts, Blaine R. NPJ Parkinsons Dis Article Characterisation and diagnosis of idiopathic Parkinson’s disease (iPD) is a current challenge that hampers both clinical assessment and clinical trial development with the potential inclusion of non-PD cases. Here, we used a targeted mass spectrometry approach to quantify 38 metabolites extracted from the serum of 231 individuals. This cohort is currently one of the largest metabolomic studies including iPD patients, drug-naïve iPD, healthy controls and patients with Alzheimer’s disease as a disease-specific control group. We identified six metabolites (3-hydroxykynurenine, aspartate, beta-alanine, homoserine, ornithine (Orn) and tyrosine) that are significantly altered between iPD patients and control participants. A multivariate model to predict iPD from controls had an area under the curve (AUC) of 0.905, with an accuracy of 86.2%. This panel of metabolites may serve as a potential prognostic or diagnostic assay for clinical trial prescreening, or for aiding in diagnosing pathological disease in the clinic. Nature Publishing Group UK 2021-10-14 /pmc/articles/PMC8516864/ /pubmed/34650080 http://dx.doi.org/10.1038/s41531-021-00239-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Klatt, Stephan Doecke, James D. Roberts, Anne Boughton, Berin A. Masters, Colin L. Horne, Malcolm Roberts, Blaine R. A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease |
title | A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease |
title_full | A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease |
title_fullStr | A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease |
title_full_unstemmed | A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease |
title_short | A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease |
title_sort | six-metabolite panel as potential blood-based biomarkers for parkinson’s disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516864/ https://www.ncbi.nlm.nih.gov/pubmed/34650080 http://dx.doi.org/10.1038/s41531-021-00239-x |
work_keys_str_mv | AT klattstephan asixmetabolitepanelaspotentialbloodbasedbiomarkersforparkinsonsdisease AT doeckejamesd asixmetabolitepanelaspotentialbloodbasedbiomarkersforparkinsonsdisease AT robertsanne asixmetabolitepanelaspotentialbloodbasedbiomarkersforparkinsonsdisease AT boughtonberina asixmetabolitepanelaspotentialbloodbasedbiomarkersforparkinsonsdisease AT masterscolinl asixmetabolitepanelaspotentialbloodbasedbiomarkersforparkinsonsdisease AT hornemalcolm asixmetabolitepanelaspotentialbloodbasedbiomarkersforparkinsonsdisease AT robertsblainer asixmetabolitepanelaspotentialbloodbasedbiomarkersforparkinsonsdisease AT klattstephan sixmetabolitepanelaspotentialbloodbasedbiomarkersforparkinsonsdisease AT doeckejamesd sixmetabolitepanelaspotentialbloodbasedbiomarkersforparkinsonsdisease AT robertsanne sixmetabolitepanelaspotentialbloodbasedbiomarkersforparkinsonsdisease AT boughtonberina sixmetabolitepanelaspotentialbloodbasedbiomarkersforparkinsonsdisease AT masterscolinl sixmetabolitepanelaspotentialbloodbasedbiomarkersforparkinsonsdisease AT hornemalcolm sixmetabolitepanelaspotentialbloodbasedbiomarkersforparkinsonsdisease AT robertsblainer sixmetabolitepanelaspotentialbloodbasedbiomarkersforparkinsonsdisease |